Attorney Docket No.: 44368-0005 C1

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION	,
Inventor(s): Palani Balu	) Art Unit: 1656
Application No.: 10/737,245	) Examiner: Kam, Chih Min
Filing Date: December 15, 2003	Confirmation No. 5841
Title: Novel Peptide Dimers as Agonists of the Erythropoietin (EPO) Receptor, and Associated Methods of Synthesis and Use	) ) )

## INFORMATION DISCLOSURE STATEMENT

## UNDER 37 C.F.R. §1.97

VIA EFS

DATE: January 17, 2008

Mail Stop: RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir or Madam:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy is provided of each foreign patent, each cited pending unpublished U.S. application, and all additional publications other than U.S. patents and U.S. patent application publications. 37 C.F.R. §§1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609. The reference was cited the office action for the corresponding European patent application.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

	This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):				
		(1)	It is being filed within 3 month continued prosecution applicati	s of the application filing date and is other than a on under § 1.53(d)	
		(2)	It is being filed within 3 month	s of entry of a national stage	
	$\boxtimes$	(3)		date of the first Office Action on the merits	
		(4)	OR It is being filed before the maili request for continued examinat	ng of a first Office Action after the filing of a on under § 1.114.	
	37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:				
		a certification as specified in §1.97(e) is provided below; or			
			f \$180.00 as set forth in \$1.17(p) ment of other papers filed togeth	is authorized below, enclosed, or included with er with this statement.	
	37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:				
	A.	a certif	tification as specified in §1.97(e) is completed below; and		
	<ul> <li>a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and</li> </ul>				
	C.	C. a fee of \$130.00 as set forth in \$1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.			
	Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. <u>08-1641 (Docket No.: 44368-0005 C1)</u> .				
				Respectfully submitted,	
				HELLER EHRMAN LLP	
Dated:	Janu	ary 17, 2	2008	By: O.P. Benhadt	
				Jeffery P. Bernhardt Reg. No.: 54,997	

HELLER EHRMAN LLP 275 Middlefield Road Menlo Park, CA 94025-3506 Telephone: 1.650.324.7000 Facsimile: 1.650.324.0638

Customer No.: 25213